Viral pneumonia
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Inflammation of the lung parenchyma that is caused by a viral infection.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Viral pneumonia
- Therapeutic area
- Infectious Disease
- viral pneumonia
- Viruses caused pneumonia
- Viruses pneumonia
- Severity
- Severe
- Acquired
- Inflammatory
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0006012
- Parent condition
- MONDO:0005249
Related records
Broader conditions (17)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Inflammatory disease
- Lower respiratory tract disorder
- Lung disorder
- Pneumonia
- Pneumonitis
- Primary viral infectious disease
- Respiratory system disorder
- Respiratory tract infectious disorder
- Viral infectious disease
- Viral respiratory tract infection
Narrower conditions (2)
- Cytomegalovirus pneumonia
- Cytomegalovirus pneumonia due to NOS2 deficiency
Trials (154)
- "Efesovir" (FS-1) for COVID-19, Phase 2
- A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
- A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
- A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
- A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia
- A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
- Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia
- Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
- AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes
- ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
- Anti Infective Agents Impact in COVID-19 Pneumonia
- Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19
- Antiviral Drugs on the Treatment of SARS-CoV-2
- Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection
- Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays
Drugs in development (24)
- Aspirin Phase 2
- Azithromycin Phase 3
- Chloroquine phosphate Phase 2
- Clopidogrel Phase 2
- Colchicine Phase 2
- Dexamethasone Phase 3
- Favipiravir Phase 1
- Fondaparinux Phase 2
- Hydrocortisone Phase 3
- Hydroxychloroquine Phase 3
- Ibudilast Phase 2
- Interferon beta-1A Phase 2
- Mefloquine Phase 2
- Nitric oxide Phase 2
- Nivolumab Phase 2
- Pembrolizumab Phase 2
- Prednisone Phase 2
- Ravulizumab Phase 3
- Remdesivir Phase 1
- Reparixin Phase 3